trending Market Intelligence /marketintelligence/en/news-insights/trending/Jxt52uqrtVk8956anvw-0w2 content esgSubNav
In This List

AbbVie, Principia Biopharma terminate immunology collaboration

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


AbbVie, Principia Biopharma terminate immunology collaboration

AbbVie Inc. and Principia Biopharma Inc. mutually agreed to end a collaboration for the development of potential drugs known as oral immunoproteasome inhibitors.

Under the 2017 agreement, the companies were partnering to conduct research and pre-clinical studies of the potential treatments for autoimmune and inflammatory disorders. AbbVie was meant to initiate clinical development and commercialize the compounds discovered from the partnership.

South San Francisco, Calif.-based Principia has reacquired the rights to the program, with the termination effective in March.